Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Aetna inks three-year agreement with HHC

Aetna announced today that it has reached an agreement with the New York City Health and Hospitals Corporation (HHC) to offer Aetna members in New York City in-network access to in-patient and out-patient services from HHC’s 11 acute care hospitals, six Diagnostic and Treatment Centers and four nursing homes.

2 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

St. David's Medical Center to use FDA cleared CARTO 3 Navigation System for treating cardiac arrhythmia

On Monday, November 2, 2009, Andrea Natale, M.D., F.A.C.C., F.H.R.S., an electrophysiologist and executive medical director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center, will be the first physician in the United States to perform an ablation procedure to treat a patient with a cardiac arrhythmia, commonly known as an irregular heart rhythm, using the newly FDA-cleared CARTO® 3 Navigation System.

2 Nov 2009

MTD Products and AHA team up to promote heart health and winter safety

What do sipping cocoa, snuggling under blankets and heart attacks all have in common? They are all more common during the cold winter months.

2 Nov 2009

Dietary cholesterol is not a primary factor for coronary heart disease

Contrary to the established view, current data suggest that dietary cholesterol is not a primary factor of or causes heart disease - with the possible exception of the genetic forms of familial hypercholesterolemias. For instance, recent clinical trials evaluating the effect of cholesterol-lowering drugs on the development of chronic heart failure, diabetes and stroke have yielded disappointing results.

2 Nov 2009

American Diabetes Association launches "Stop Diabetes" campaign

Americans earn a failing grade on diabetes awareness, based on survey results released today by the American Diabetes Association. In general, Americans earned a 51% when asked a series of questions about a disease so common that it strikes every 20 seconds. The survey results revealed that many diabetes myths and misconceptions still exist, while the disease's prevalence continues to rise.

2 Nov 2009

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

2 Nov 2009

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

Conference to address the need for gender specific diagnostic strategies for women

The 'Red Alert for Women's Hearts' conference, taking place on 5 November 2009, at the European Heart House, Sophia Antipolis, France, will address the subject of Women and CVD. The conference is jointly organised by the European Society of Cardiology (ESC) and European Heart Network (EHN), as part of Work Package 6 of the EuroHeart project .

31 Oct 2009

WakeMed Health & Hospitals and SCA team up to explore partnership opportunities

WakeMed Health & Hospitals and Surgical Care Affiliates (SCA) have entered into a Letter of Understanding (LOU) under which the two organizations will explore partnership opportunities.

31 Oct 2009

Study: Gene therapy can reduce symptoms of Huntington's disease

Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.

31 Oct 2009

Geron plans to advance clinical program for spinal cord injury

Geron Corporation today announced the company’s plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.

31 Oct 2009

New teleneurology medicine program to provide 24-hour emergency services launched

Rural and small, suburban hospitals in North Carolina and Virginia can now provide a higher level of emergency stroke and critical neurology care, 24 hours a day, 365 days a year, as part of a new teleneurology medicine program announced Oct. 26, 2009, by Forsyth Medical Center (FMC).

31 Oct 2009

Individualized MicroNutrient Testing for patients

In response to the current trend toward personalized medicine, the Beaumont Weight Control Center, affiliated with Beaumont Hospitals, a major Detroit-area health system, now offers individualized MicroNutrient Testing for patients.

31 Oct 2009

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

MSC's Quality Initiative Programs to support best practice-based training for healthcare professionals

MSC's Sepsis Program has demonstrated the capability to increase tested knowledge in early identification and treatment of sepsis among trainees by over 46 percent. The program has been delivered to healthcare providers representing a range of institutions, from community hospitals to large academic teaching hospitals, demonstrating wide applicability among healthcare professionals with varied clinical backgrounds and previous training.

30 Oct 2009

Isotechnika Pharma develops portfolio of NICAMs with potent cyclophilin inhibition

Isotechnika Pharma Inc. today announced that it has developed a portfolio of non-immunosuppressive cyclosporine analogue molecules (NICAMs) with potent cyclophilin inhibition. Cyclophilin inhibition has garnered considerable attention as a novel therapy in the treatment of a wide range of diseases including hepatitis C, stroke, and chronic neurological disorders such as Parkinson's, Lou Gehrig's, and Alzheimer's.

30 Oct 2009

Case Western Reserve awarded $14.7M to lead study on effects of lowering systolic blood pressure

Case Western Reserve University School of Medicine has received a $14.7 million, nine-year contract from the National Institutes of Health to be one of five institutions to lead a trial to determine if lowering systolic blood pressure in hypertensive patients, without diabetes, to below the currently recommended level can reduce the incidence of cardiovascular and kidney disease and slow cognitive decline.

30 Oct 2009

Stroke News and Research

Further Reading

Aetna inks three-year agreement with HHC

NIH awards $2 million grant for sickle cell disease research

St. David's Medical Center to use FDA cleared CARTO 3 Navigation System for treating cardiac arrhythmia

MTD Products and AHA team up to promote heart health and winter safety

Dietary cholesterol is not a primary factor for coronary heart disease

American Diabetes Association launches "Stop Diabetes" campaign

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Amgen publishes Phase 3 study results of Aranesp

Shire announces Phase IIIb study results of Daytrana

Conference to address the need for gender specific diagnostic strategies for women

WakeMed Health & Hospitals and SCA team up to explore partnership opportunities

Study: Gene therapy can reduce symptoms of Huntington's disease

Geron plans to advance clinical program for spinal cord injury

New teleneurology medicine program to provide 24-hour emergency services launched

Individualized MicroNutrient Testing for patients

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

MSC's Quality Initiative Programs to support best practice-based training for healthcare professionals

Isotechnika Pharma develops portfolio of NICAMs with potent cyclophilin inhibition

Case Western Reserve awarded $14.7M to lead study on effects of lowering systolic blood pressure

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News